Trial Site Detail

 

Drug:
BIIB021 (CNF2024)
Trial:
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
Conditions: Gastrointestinal Stromal Tumor
Trial Status:
Completed

 

Memorial Sloan Kettering

1275 York Ave     
New York , NY 10065
USA

 

Principal Investigator:
Robert Maki, MD
Contact:
Activation Status of this Site:
Closed
Notes about this Site:
Memorial Sloan Kettering Website:
http://www.mskcc.org/mskcc/html/2270.cfm?Tab=All

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.